Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Novartis has announced the expansion of its community health programs to improve…
Novartis agrees to acquire Excellergy, Inc.
Novartis has agreed to acquire Excellergy, adding a next-generation anti-IgE antibody therapy…
Saudi Arabia’s Riyadh to Host Landmark Life Sciences Summit in May 2026
Riyadh will host CPHI Middle East and BIO Middle East from May…
WHO Strengthens Global Efforts to Ensure Access to Leprosy Treatment
WHO renews its commitment to global leprosy elimination by ensuring continued access…
FDA Grants Breakthrough Therapy Designation to Novartis’ Ianalumab for Sjögren’s Disease
The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s…
The Emirates Drug Foundation approves gene therapy for gene replacement in a new age group of spinal muscular atrophy patients.
The Emirates Drug Authority (EDA) has announced the approval of Itvisma, a…
Novartis Leads Nationwide Effort to Bring Breast Cancer Awareness and Early Detection to UAE Workplaces
In collaboration with the Friends of Cancer Patients’ Pink Caravan, the initiative…
Novartis Receives Approval for First Malaria Medicine for Newborn Babies and Young Infants
Novartis announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first…
Karen Hale Named Chief Legal and Compliance Officer at Novartis
Novartis announced the appointment of Karen Hale to the expanded role of…
ADPHC and Novartis Team Up to Tackle Chronic Diseases in Abu Dhabi
In a major step to combat non-communicable diseases (NCDs), the Abu Dhabi…
